We are incredibly excited to attend the Protein and Antibody Engineering Summit in Lisbon, Portugal! This is the largest protein and antibody engineering event in Europe and has been described as "the best biologics technology meeting in Europe." New this year is expanded coverage of AI/ML, multispecific antibodies, antibody-drug conjugates, and an entire stream devoted to Oncology.
Find us at booth #249!
PEGS Europe Seminar:
Leveraging High-Throughput Platforms for the Discovery of Bispecific Antibodies
Thursday, November 13, 9:30AM WET at Engineering the Next Generation of Bispecific Antibodies
Details here: https://www.pegsummiteurope.com/engineering-bispecifics
About the Seminar:
We present a high-throughput platform to accelerate antibody discovery by integrating antibody production, NGS screening, and high-throughput automated workflows. This enables rapid identification and scalable production of thousands of antibody candidates, significantly reducing timelines and overcoming the bottlenecks of traditional methods.
Presenter Bio: Crystal brings over eight years of expertise in antibody discovery and protein engineering, offering tailored technical guidance to ensure seamless transitions from pilot projects to large-scale, high-throughput (>1,000) antibody production.
Poster Presentation:
Accelerating Antibody Discovery: High-Throughput Solutions for Producing Antibodies at Scale
Prassanna Rao, Crystal M. Richardson, Riley Graham, Cassandra Koole, and Sumit Kumar
Poster Session B: Wednesday (afternoon), November 12 - Thursday, November 13
The rapid identification and production of antibodies is essential for advancing therapeutic innovation. Traditional antibody discovery methods, such as phage display, yeast display, and hybridoma technologies, often struggle with limitations in throughput and efficiency. In this context, we introduce a high-throughput solution to significantly accelerate antibody lead discovery and production. This approach leverages state-of-the-art sequencing technologies, including next-generation sequencing with bulk or single-cell profiling to enable rapid identification of variable regions. Additionally, the workflow integrates codon-optimized mammalian expression vectors, enabling a 2-4x boost in expression levels during scalable, high-throughput antibody production. Combined with seamless automated processing, this system empowers researchers to identify and produce thousands to tens of thousands of antibody candidates in parallel for screening. Taken together, this streamlined workflow addresses bottlenecks in traditional processes, offering a transformative advancement for therapeutic antibody discovery.
Design the next Guardian of the Genome trading card! Submit your drawing by December 5, 2025 here: https://web.genewiz.com/guardians-of-the-genome-contest.
Then follow us on Bluesky, LinkedIn, or X to see if your drawing is highlighted.